# A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

> **NCT06846866** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 74 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** BMS-986419
- **DRUG:** BMS-986419 Matching Placebo
- **DRUG:** Moxifloxacin
- **DRUG:** Moxifloxacin Matching Placebo

## Key facts

- **NCT ID:** NCT06846866
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-27
- **Primary completion:** 2025-10-21
- **Final completion:** 2025-10-21
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06846866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06846866, "A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06846866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*